 <h1>Calcimar Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>calcitonin</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about calcitonin. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Calcimar.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to calcitonin: injection solution</i></p><p>Other dosage forms:</p><ul><li>nasal spray</li></ul><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, calcitonin (the active ingredient contained in Calcimar) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking calcitonin:</p><p>
<i>Incidence not known</i>
</p><ul>
<li>Blurred vision</li>
<li>chills or fever</li>
<li>cough</li>
<li>difficulty with breathing</li>
<li>difficulty with swallowing</li>
<li>dizziness</li>
<li>frequent urination</li>
<li>headache</li>
<li>joint pain</li>
<li>muscle aches and pains</li>
<li>muscle cramps in the hands, arms, feet, legs, or face</li>
<li>nausea or vomiting</li>
<li>puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue</li>
<li>seizures</li>
<li>skin rash or itching</li>
<li>slow or fast heartbeat</li>
<li>sweating</li>
<li>swelling of the hands, ankles, feet, or lower legs</li>
<li>tightness in the chest</li>
<li>tingling of the hands or feet</li>
<li>trembling or shaking of the legs, arms, hands or feet</li>
<li>trouble sleeping</li>
<li>unusual tiredness or weakness</li>
<li>unusual weight gain or loss</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of calcitonin may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Red streaks on the skin</li>
<li>swelling, tenderness, or pain at the injection site</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Feeling of warmth</li>
<li>redness of the face, neck, arms, and occasionally, upper chest</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Abdominal or stomach pain</li>
<li>changes in vision</li>
<li>diarrhea</li>
<li>pain in the eyes</li>
<li>poor appetite</li>
<li>waking to urinate at night</li>
</ul><p>
<div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to calcitonin: injectable solution, nasal spray</i></p><h3>General</h3><p>The most commonly reported adverse effects with use of the injection are nausea, injection site inflammation, and flushing of face or hands; rhinitis, epistaxis, back pain, arthralgia, and headache have been reported with use of the nasal spray.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (10%)</p>
<p><b>Common</b> (1% to 10%): Abdominal pain</p>
<p><b>Frequency not reported</b>: Salty taste, diarrhea</p><p>With parenteral use, nausea with or without vomiting appears most frequently upon treatment initiation and tends to decrease or disappear with continued use.</p><h3>Local</h3><p><b>Very common</b> (10% or more): Inflammatory reactions at the site of injection</p><h3>Metabolic</h3><p><b>Frequency not reported</b>: Poor appetite</p>
<p><b>Postmarketing reports</b>: Hypocalcemia with tetany (muscle cramps, twitching) and seizure activity</p><h3>Hypersensitivity</h3><p><b>Postmarketing reports</b>: Serious hypersensitivity reactions including bronchospasm, swelling of the tongue or throat, anaphylactic shock, and death due to anaphylaxis</p><h3>Respiratory</h3><p>Symptoms of nose include: Nasal crusts, dryness, redness or erythema, nasal sores, irritation, itching, thick feeling, soreness, pallor, infection, stenosis, runny/blocked, small wound, bleeding wound, tenderness, uncomfortable feeling, and sore across bridge of nose.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Rhinitis (12%), symptoms of nose (11%) </p>
<p><b>Common</b> (1% to 10%): Epistaxis, sinusitis, upper respiratory tract infection, bronchospasm </p>
<p><b>Postmarketing reports</b>: Cough, dyspnea<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Frequency not reported</b>: Pedal edema</p>
<p><b>Postmarketing reports</b>: Edema (facial, peripheral, and generalized), hypertension, chest pain syncope, vasodilation</p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Dizziness, paresthesia </p>
<p><b>Postmarketing reports</b>: Headache, tremor, seizure, loss of taste/smell</p><h3>Immunologic</h3><p><b>Postmarketing reports</b>: Anti-drug antibodies</p><p>For those that antibody studies were done, circulating antibodies to calcitonin were found in about 50% of patients with Paget's disease after 2 to 18 months of treatment.  Circulating antibodies have also been reported with use of the nasal spray.</p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Flushing of hand or face, erythematous rash </p>
<p><b>Frequency not reported</b>: Skin rashes and pruritus of ear lobes</p>
<p><b>Postmarketing reports</b>: Urticaria, rash/dermatitis, pruritus, alopecia, increased sweating</p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Back pain, arthralgia, arthrosis, myalgia </p>
<p><b>Postmarketing reports</b>: Musculoskeletal pain<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Common</b> (1% to 10%): Lymphadenopathy</p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Abnormal lacrimation, conjunctivitis </p>
<p><b>Frequency not reported</b>: Eye pain</p>
<p><b>Postmarketing reports</b>: Visual disturbance, visual or hearing impairment, tinnitus</p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Depression</p><h3>Genitourinary</h3><p><b>Frequency not reported</b>: Nocturia</p>
<p><b>Postmarketing reports</b>: Polyuria</p><h3>Oncologic</h3><p><b>Common</b> (1% to 10%): Malignancy</p><p>A meta-analysis of 21 randomized, controlled clinical trials among patients using the nasal spray or an investigational oral formulation found the overall incidence of malignancy in patients receiving this drug was 4.1% (254/6151) compared to 2.9% (137/4732) in placebo.  An analyses of just nasal spray trials showed the incidence was similar (4.5% vs 2.3%).  Data has shown the increased risk was heavily influenced by a single large 5-year trial.  A mechanism for this increased risk has not been identified.</p><h3>Other</h3><p><b>Common</b> (1% to 10%): Influenza-like symptoms</p>
<p><b>Frequency not reported</b>: Feverish sensation</p>
<p><b>Postmarketing reports</b>: Fatigue</p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Miacalcin Nasal Spray (calcitonin nasal)." Novartis Pharmaceuticals, East Hanover, NJ. </p><p id="ref_2">2. "Product Information. Miacalcin Injection, Synthetic (calcitonin)." Novartis Pharmaceuticals, East Hanover, NJ. </p></div>
<div class="more-resources" id="moreResources">
<h2>More about Calcimar (calcitonin)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Drug class: calcitonin</li>
</ul>
<h3>Consumer resources</h3>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Miacalcin, Fortical, Miacalcin Nasal</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Hypercalcemia</li>
<li>Osteogenesis Imperfecta</li>
<li>Osteoporosis</li>
<li>Paget's Disease</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to calcitonin: injectable solution, nasal spray</i></p><h3>General</h3><p>The most commonly reported adverse effects with use of the injection are nausea, injection site inflammation, and flushing of face or hands; rhinitis, epistaxis, back pain, arthralgia, and headache have been reported with use of the nasal spray.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (10%)</p><p><b>Common</b> (1% to 10%): Abdominal pain</p><p><b>Frequency not reported</b>: Salty taste, diarrhea</p><p>With parenteral use, nausea with or without vomiting appears most frequently upon treatment initiation and tends to decrease or disappear with continued use.</p><h3>Local</h3><p><b>Very common</b> (10% or more): Inflammatory reactions at the site of injection</p><h3>Metabolic</h3><p><b>Frequency not reported</b>: Poor appetite</p><p><b>Postmarketing reports</b>: Hypocalcemia with tetany (muscle cramps, twitching) and seizure activity</p><h3>Hypersensitivity</h3><p><b>Postmarketing reports</b>: Serious hypersensitivity reactions including bronchospasm, swelling of the tongue or throat, anaphylactic shock, and death due to anaphylaxis</p><h3>Respiratory</h3><p>Symptoms of nose include: Nasal crusts, dryness, redness or erythema, nasal sores, irritation, itching, thick feeling, soreness, pallor, infection, stenosis, runny/blocked, small wound, bleeding wound, tenderness, uncomfortable feeling, and sore across bridge of nose.<sup>[Ref]</sup></p><p><b>Very common</b> (10% or more): Rhinitis (12%), symptoms of nose (11%) </p><p><b>Common</b> (1% to 10%): Epistaxis, sinusitis, upper respiratory tract infection, bronchospasm </p><p><b>Postmarketing reports</b>: Cough, dyspnea<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Frequency not reported</b>: Pedal edema</p><p><b>Postmarketing reports</b>: Edema (facial, peripheral, and generalized), hypertension, chest pain syncope, vasodilation</p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Dizziness, paresthesia </p><p><b>Postmarketing reports</b>: Headache, tremor, seizure, loss of taste/smell</p><h3>Immunologic</h3><p><b>Postmarketing reports</b>: Anti-drug antibodies</p><p>For those that antibody studies were done, circulating antibodies to calcitonin were found in about 50% of patients with Paget's disease after 2 to 18 months of treatment.  Circulating antibodies have also been reported with use of the nasal spray.</p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Flushing of hand or face, erythematous rash </p><p><b>Frequency not reported</b>: Skin rashes and pruritus of ear lobes</p><p><b>Postmarketing reports</b>: Urticaria, rash/dermatitis, pruritus, alopecia, increased sweating</p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Back pain, arthralgia, arthrosis, myalgia </p><p><b>Postmarketing reports</b>: Musculoskeletal pain<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Common</b> (1% to 10%): Lymphadenopathy</p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Abnormal lacrimation, conjunctivitis </p><p><b>Frequency not reported</b>: Eye pain</p><p><b>Postmarketing reports</b>: Visual disturbance, visual or hearing impairment, tinnitus</p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Depression</p><h3>Genitourinary</h3><p><b>Frequency not reported</b>: Nocturia</p><p><b>Postmarketing reports</b>: Polyuria</p><h3>Oncologic</h3><p><b>Common</b> (1% to 10%): Malignancy</p><p>A meta-analysis of 21 randomized, controlled clinical trials among patients using the nasal spray or an investigational oral formulation found the overall incidence of malignancy in patients receiving this drug was 4.1% (254/6151) compared to 2.9% (137/4732) in placebo.  An analyses of just nasal spray trials showed the incidence was similar (4.5% vs 2.3%).  Data has shown the increased risk was heavily influenced by a single large 5-year trial.  A mechanism for this increased risk has not been identified.</p><h3>Other</h3><p><b>Common</b> (1% to 10%): Influenza-like symptoms</p><p><b>Frequency not reported</b>: Feverish sensation</p><p><b>Postmarketing reports</b>: Fatigue</p><p id="ref_1">1. "Product Information. Miacalcin Nasal Spray (calcitonin nasal)." Novartis Pharmaceuticals, East Hanover, NJ. </p><p id="ref_2">2. "Product Information. Miacalcin Injection, Synthetic (calcitonin)." Novartis Pharmaceuticals, East Hanover, NJ. </p><h2>More about Calcimar (calcitonin)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Drug class: calcitonin</li>
</ul><h3>Consumer resources</h3><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Hypercalcemia</li>
<li>Osteogenesis Imperfecta</li>
<li>Osteoporosis</li>
<li>Paget's Disease</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>